Fundraising Fox

A-Alpha Bio

Seattle, US · Founded 2017 · Delaware corporation · 7 known investors

aalphabio.com ↗

A-Alpha Bio uses synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions for pharmaceutical discovery and development. The company operates experimental (AlphaSeq) and computational (AlphaBind) platforms to accelerate the design of novel therapeutics.

AI & Machine LearningBiotechDeep Techin /aalphabio@AAlphaBio

Founders & leadership

DY
David Younger, PhDChief Executive Officer & Co-Founder
RL
Randolph Lopez, PhDChief Technology Officer & Co-Founder
DY
David YoungerExecutive Officer, Director, Promoter

Investors · 7

Angel Collective Opportunity FundSan Francisco
Breakout VenturesSan Francisco · $500K – $6M
Farvatn VentureBergen
Lux CapitalNew York · $100K – $100M
Madrona Venture GroupSeattle · $2M – $10M
Boom Capital VenturesreportedSan Francisco · $50K – $300Kvia Celestine Schnugg · inferred
OS FundreportedPark Ridge · $1M – $2M

Reported raises · per SEC filings

Form D private placements
▶$20.3MraisedSep 2021 · 18 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ben AskewDirector
  • Randolph Lopez BarrezuetaDirector
  • Matt McIlwainDirector
  • David YoungerExecutive Officer, Director
Offering amount
$20.3M
Amount sold
$20.3M
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.8MraisedSep 2019 · 15 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • David YoungerExecutive Officer, Director, Promoter
Offering amount
$2.8M
Amount sold
$2.8M
First sale
Sep 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news